Travere Therapeutics (TVTX) to Release Quarterly Earnings on Thursday

Travere Therapeutics (NASDAQ:TVTX) is projected to post its quarterly earnings results after the market closes on Thursday, February 20th. Analysts expect Travere Therapeutics to post earnings of ($0.58) per share and revenue of $72.38 million for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Travere Therapeutics Trading Down 1.1 %

NASDAQ:TVTX opened at $22.66 on Wednesday. Travere Therapeutics has a 1-year low of $5.12 and a 1-year high of $25.29. The business’s 50-day moving average price is $19.38 and its two-hundred day moving average price is $16.38. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. The firm has a market capitalization of $1.77 billion, a price-to-earnings ratio of -4.98 and a beta of 0.72.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. HC Wainwright increased their target price on Travere Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a research note on Wednesday, January 15th. Evercore ISI raised their price target on Travere Therapeutics from $33.00 to $45.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 12th. Cantor Fitzgerald started coverage on Travere Therapeutics in a research report on Friday, January 10th. They set an “overweight” rating on the stock. Piper Sandler raised their price target on Travere Therapeutics from $12.00 to $22.00 and gave the stock a “neutral” rating in a research report on Thursday, November 14th. Finally, Scotiabank raised their price target on Travere Therapeutics from $27.00 to $32.00 and gave the stock a “sector outperform” rating in a research report on Wednesday, February 12th. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, Travere Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $27.77.

Insider Buying and Selling

In other Travere Therapeutics news, CAO Sandra Calvin sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 26th. The stock was sold at an average price of $17.22, for a total value of $258,300.00. Following the completion of the transaction, the chief accounting officer now directly owns 54,927 shares in the company, valued at $945,842.94. This trade represents a 21.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP William E. Rote sold 2,437 shares of the firm’s stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $19.46, for a total value of $47,424.02. Following the completion of the transaction, the senior vice president now owns 83,170 shares of the company’s stock, valued at approximately $1,618,488.20. This represents a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 218,425 shares of company stock worth $4,674,259. 3.75% of the stock is owned by corporate insiders.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.